Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cullinan Therapeutics, Inc. (CGEM : NSDQ)

• Company Description    Cullinan Therapeutics Inc. is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. The company's product pipeline consists CLN-978. Cullinan Therapeutics Inc., formerly known as Cullinan Oncology Inc., is based in CAMBRIDGE, Mass. Number of Employees: 109

• Price / Volume Information    Yesterday's Closing Price: $13.84 Daily Weekly Monthly 20 Day Moving Average: 972,749 shares Shares Outstanding: 61.46 (millions) Market Capitalization: $850.58 (millions) Beta: -0.09 52 Week High: $16.74 52 Week Low: $5.68 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 6.87% 1.65% 12 Week -9.01% -15.88% Year To Date 33.72% 24.18%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ONE MAIN STREET SUITE 1350 - CAMBRIDGE,MA 02142 USA ph: 617-410-4650 fax: - nsmith@cullinantx.com http://www.cullinanoncology.com

• General Corporate Information    Officers Nadim Ahmed - President; Chief Executive Officer and Director Mary Kay Fenton - Chief Financial Officer Andrew Allen - Director Mittie Doyle - Director David Meek - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 230031106 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 61.46 Most Recent Split Date: (:1) Beta: -0.09 Market Capitalization: $850.58 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.76 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.07 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.32 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -1.35% vs. Previous Quarter: 2.60% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -51.45 12/31/25 - -46.19 09/30/25 - -41.58 ROA 03/31/26 - -47.64 12/31/25 - -43.27 09/30/25 - -39.31 Current Ratio 03/31/26 - 10.28 12/31/25 - 10.25 09/30/25 - 10.45 Quick Ratio 03/31/26 - 10.28 12/31/25 - 10.25 09/30/25 - 10.45 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 5.96 12/31/25 - 6.92 09/30/25 - 7.64 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©